Dermatology (Basel, Switzerland) · 2015
Positive Direct Immunofluorescence Is of Better Value than ELISA-BP180 and ELISA-BP230 Values for the Prediction of Relapse after Treatment Cessation in Bullous Pemphigoid: A Retrospective Study of 97 Patients.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ingen-Housz-Oro Saskia, Plée Julie, Belmondo Thibaut, Maizières Michaël, Pham Bach-Nga, Hüe Sophie, Ortonne Nicolas, Durlach Anne, Wolkenstein Pierre, Chosidow Olivier, Bernard Philippe
Аннотация
BACKGROUND: ELISA-BP180 values and direct immunofluorescence (DIF) are prognostic factors for relapse after treatment cessation in bullous pemphigoid (BP).
OBJECTIVE: To determine the relevance of ELISA-BP230 antibodies for predicting relapse 6 months after treatment cessation.
METHODS: We retrospectively selected patients with BP and available data from ELISA-BP180 and -BP230 and DIF performed at treatment cessation. The rate of relapse was calculated at 6 months. We compared ELISA-BP180 and -BP230 values and DIF in patients with relapse and remission.
RESULTS: We included 97 patients. At 6 months, 25.6% of patients showed relapse. The proportion of patients with an ELISA-BP230 value ≥27 UA/ml was higher, but not significantly, for those with relapse than for those with remission (p = 0.11). The frequency of positive DIF findings was significantly higher for patients with relapse (p = 0.005).
CONCLUSION: DIF is of better value than ELISA-BP180 and -230 tests to predict relapse after treatment cessation in BP.
OBJECTIVE: To determine the relevance of ELISA-BP230 antibodies for predicting relapse 6 months after treatment cessation.
METHODS: We retrospectively selected patients with BP and available data from ELISA-BP180 and -BP230 and DIF performed at treatment cessation. The rate of relapse was calculated at 6 months. We compared ELISA-BP180 and -BP230 values and DIF in patients with relapse and remission.
RESULTS: We included 97 patients. At 6 months, 25.6% of patients showed relapse. The proportion of patients with an ELISA-BP230 value ≥27 UA/ml was higher, but not significantly, for those with relapse than for those with remission (p = 0.11). The frequency of positive DIF findings was significantly higher for patients with relapse (p = 0.005).
CONCLUSION: DIF is of better value than ELISA-BP180 and -230 tests to predict relapse after treatment cessation in BP.
Предметные рубрики MeSH
Administration, CutaneousAdrenal Cortex HormonesAdultAgedAged, 80 and overAutoantibodiesAutoantigensCarrier ProteinsCytoskeletal ProteinsDystoninEnzyme-Linked Immunosorbent AssayFemaleFluorescent Antibody Technique, DirectFollow-Up StudiesHumansImmunosuppressive AgentsMaleMiddle AgedNerve Tissue ProteinsNon-Fibrillar CollagensPemphigoid, BullousPredictive Value of TestsRecurrenceRetrospective StudiesCollagen Type XVII